Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer

Cancer Immunology, Immunotherapy

Volumn 58, Issue 4, 2009, Pages 475-492

  Zhang, Tianqian ^a   Herlyn, Dorothee ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Antibody; Cancer; Chemotherapy; Immunotherapy; Lymphocyte; Vaccine

Indexed keywords

CALICHEAMICIN; CANCER VACCINE; CARMUSTINE; CD137 ANTIGEN; CETUXIMAB; CISPLATIN; CYCLIC AMP; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INOTUZUMAB OZOGAMICIN; IRINOTECAN; METHOTREXATE; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; RITUXIMAB; TEMOZOLOMIDE; TOPOTECAN; TOSITUMOMAB I 131; TRASTUZUMAB; TRIMETREXATE; UNINDEXED DRUG; VACCINIA VACCINE; VINBLASTINE;

ACTIVE IMMUNIZATION; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL DEATH; CLINICAL TRIAL; COLON CARCINOMA; GLIOBLASTOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE TRANSFER; LYMPHOCYTOPENIA; MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SQUAMOUS CELL CARCINOMA; THERAPY EFFECT; TUMOR CELL; TUMOR CELL DESTRUCTION; VACCINIA VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 59449090966     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0598-y     Document Type: Review

References (155)

1. DB Agus HI Scher B Higgins WD Fox G Heller M Fazzari C Cordon-Cardo DW Golde 1999 Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models Cancer Res 59 4761 4764
2. H Akbulut Y Tang KG Akbulut J Maynard L Zhang A Deisseroth 2006 Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer Mol Cancer Ther 5 1975 1985
3. MH Andersen RB Sorensen D Schrama IM Svane JC Becker P Thor Straten 2008 Cancer treatment: the combination of vaccination with other therapies Cancer Immunol Immunother 57 1735 1743
4. SJ Antonia N Mirza I Fricke A Chiappori P Thompson N Williams G Bepler G Simon W Janssen JH Lee K Menander S Chada DI Gabrilovich 2006 Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer Clin Cancer Res 12 878 887
5. V Appay V Voelter N Rufer S Reynard C Jandus D Gasparini D Lienard DE Speiser P Schneider JC Cerottini P Romero S Leyvraz 2007 Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma J Immunother 30 240 250
6. PM Arlen JL Gulley C Parker L Skarupa M Pazdur D Panicali P Beetham KY Tsang DW Grosenbach J Feldman SM Steinberg E Jones C Chen J Marte J Schlom W Dahut 2006 A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer Clin Cancer Res 12 1260 1269
7. D Balin-Gauthier JP Delord P Rochaix V Mallard F Thomas I Hennebelle R Bugat P Canal C Allal 2006 In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR Cancer Chemother Pharmacol 57 709 718
8. J Baselga L Norton J Albanell YM Kim J Mendelsohn 1998 Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts Cancer Res 58 2825 2831
9. J Baselga L Norton H Masui A Pandiella K Coplan WH Miller Jr J Mendelsohn 1993 Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies J Natl Cancer Inst 85 1327 1333
10. J Baselga D Pfister MR Cooper R Cohen B Burtness M Bos G D'Andrea A Seidman L Norton K Gunnett J Falcey V Anderson H Waksal J Mendelsohn 2000 Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin J Clin Oncol 18 904 914
11. J Baselga JM Trigo J Bourhis J Tortochaux H Cortes-Funes R Hitt P Gascon N Amellal A Harstrick A Eckardt 2005 Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck J Clin Oncol 23 5568 5577
12. D Berd 1989 Low doses of chemotherapy to inhibit suppressor T cells Prog Clin Biol Res 288 449 458
13. D Berd MJ Mastrangelo 1988 Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells Cancer Res 48 1671 1675
14. G Bianchi J Albanell W Eiermann G Vitali D Borquez L Vigano R Molina G Raab A Locatelli B Vanhauwere L Gianni J Baselga 2003 Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer Clin Cancer Res 9 5944 5951
15. E Bonmassar C Testorelli P Franco A Goldin G Cudkowicz 1975 Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs Cancer Res 35 1957 1962
16. M Bouzani T Karmiris D Rontogianni S Delimpassi J Apostolidis M Mpakiri E Nikiforakis 2006 Disseminated intravascular B-cell lymphoma: clinicopathological features and outcome of three cases treated with anthracycline-based immunochemotherapy Oncologist 11 923 928
17. CJ Bruns MT Harbison DW Davis CA Portera R Tsan DJ McConkey DB Evans JL Abbruzzese DJ Hicklin R Radinsky 2000 Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms Clin Cancer Res 6 1936 1948
18. O Bruserud O Wendelboe 2001 Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? Expert Opin Biol Ther 1 1005 1016
19. JL Cantrell JJ Killion GM Kollmorgen 1976 Correlations between humoral immunity and successful chemotherapy-immunotherapy Cancer Res 36 3051 3057
20. N Casares MO Pequignot A Tesniere F Ghiringhelli S Roux N Chaput E Schmitt A Hamai S Hervas-Stubbs M Obeid F Coutant D Metivier E Pichard P Aucouturier G Pierron C Garrido L Zitvogel G Kroemer 2005 Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J Exp Med 202 1691 1701
21. AP Castano P Mroz MR Hamblin 2006 Photodynamic therapy and anti-tumour immunity Nat Rev Cancer 6 535 545
22. Y Chalandon JP Mach A Pelegrin S Folli F Buchegger 1992 Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations Anticancer Res 12 1131 1139
23. F Ciardiello R Bianco V Damiano S De Lorenzo S Pepe S De Placido Z Fan J Mendelsohn AR Bianco G Tortora 1999 Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 Clin Cancer Res 5 909 916
24. F Ciardiello V Damiano R Bianco C Bianco G Fontanini M De Laurentiis S De Placido J Mendelsohn AR Bianco G Tortora 1996 Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A J Natl Cancer Inst 88 1770 1776
25. B Coiffier 2002 Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma Semin Oncol 29 18 22
26. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah P Morel E Van Den Neste G Salles P Gaulard F Reyes P Lederlin C Gisselbrecht 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242
27. P Correale MT Del Vecchio G Di Genova GG Savellini M La Placa C Terrosi M Vestri R Urso F Lemonnier A Aquino E Bonmassar G Giorgi G Francini MG Cusi 2005 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine J Natl Cancer Inst 97 1437 1445
28. P Correale MT Del Vecchio M La Placa F Montagnani G Di Genova GG Savellini C Terrosi S Mannucci G Giorgi G Francini MG Cusi 2008 Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs J Immunother 31 132 147
29. MS Czuczman 1999 CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma Semin Oncol 26 88 96
30. MS Czuczman 2002 Immunochemotherapy in indolent non-Hodgkin's lymphoma Semin Oncol 29 11 17
31. MS Czuczman AJ Grillo-Lopez CA White M Saleh L Gordon AF LoBuglio C Jonas D Klippenstein B Dallaire C Varns 1999 Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 17 268 276
32. G Del Poeta M Ilaria Del Principe F Buccisano L Maurillo P Niscola A Venditti S Amadori 2006 Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia Expert Rev Anticancer Ther 6 1787 1800
33. A Demidem T Lam S Alas K Hariharan N Hanna B Bonavida 1997 Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs Cancer Biother Radiopharm 12 177 186
34. SJ DeNardo DL Kukis LA Kroger RT O'Donnell KR Lamborn LA Miers DG DeNardo CF Meares GL DeNardo 1997 Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts Proc Natl Acad Sci USA 94 4000 4004
35. B Desrues F Brichory H Lena P Bourguet P Delaval L Toujas L Dazord 1996 Treatment of human lung carcinoma xenografts with a combination of 131I-labelled monoclonal antibody Po66 and doxorubicin Cancer Immunol Immunother 43 269 274
36. B Desrues H Lena F Brichory MP Ramee L Toujas P Delaval L Dazord 1995 Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin Br J Cancer 72 1076 1082
37. JF DiJoseph DC Armellino ER Boghaert K Khandke MM Dougher L Sridharan A Kunz PR Hamann B Gorovits C Udata JK Moran AG Popplewell S Stephens P Frost NK Damle 2004 Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies Blood 103 1807 1814
38. JF Dijoseph MM Dougher DC Armellino DY Evans NK Damle 2007 Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia Leukemia 21 2240 2245
39. JF DiJoseph MM Dougher LB Kalyandrug DC Armellino ER Boghaert PR Hamann JK Moran NK Damle 2006 Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma Clin Cancer Res 12 242 249
40. JF DiJoseph ME Goad MM Dougher ER Boghaert A Kunz PR Hamann NK Damle 2004 Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma Clin Cancer Res 10 8620 8629
41. JF DiJoseph A Popplewell S Tickle H Ladyman A Lawson A Kunz K Khandke DC Armellino ER Boghaert P Hamann K Zinkewich-Peotti S Stephens N Weir NK Damle 2005 Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22 Cancer Immunol Immunother 54 11 24
42. ME Dudley JR Wunderlich PF Robbins JC Yang P Hwu DJ Schwartzentruber SL Topalian R Sherry NP Restifo AM Hubicki MR Robinson M Raffeld P Duray CA Seipp L Rogers-Freezer KE Morton SA Mavroukakis DE White SA Rosenberg 2002 Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 850 854
43. ME Dudley JR Wunderlich JC Yang P Hwu DJ Schwartzentruber SL Topalian RM Sherry FM Marincola SF Leitman CA Seipp L Rogers-Freezer KE Morton A Nahvi SA Mavroukakis DE White SA Rosenberg 2002 A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma J Immunother 25 243 251
44. ME Dudley JR Wunderlich JC Yang RM Sherry SL Topalian NP Restifo RE Royal U Kammula DE White SA Mavroukakis LJ Rogers GJ Gracia SA Jones DP Mangiameli MM Pelletier J Gea-Banacloche MR Robinson DM Berman AC Filie A Abati SA Rosenberg 2005 Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23 2346 2357
45. K Dunussi-Joannopoulos 2002 The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma Leuk Lymphoma 43 2075 2082
46. K Dunussi-Joannopoulos W Krenger HJ Weinstein JL Ferrara JM Croop 1997 CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment Blood 89 2915 2924
47. MJ Ehrke 2003 Immunomodulation in cancer therapeutics Int Immunopharmacol 3 1105 1119
48. LA Emens RT Reilly EM Jaffee 2005 Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity Endocr Relat Cancer 12 1 17
49. Y Eralp X Wang JP Wang MF Maughan JM Polo LB Lachman 2004 Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model Breast Cancer Res 6 R275 R283
50. Z Fan J Baselga H Masui J Mendelsohn 1993 Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts Cancer Res 53 4637 4642
51. MC Fioretti R Bianchi L Romani E Bonmassar 1983 Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity J Natl Cancer Inst 71 1247 1251
52. MC Fioretti L Romani E Bonmassar 1983 Antigenic changes related to drug action Prog Clin Biol Res 132B 435 445
53. DI Gabrilovich 2007 Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited Lancet Oncol 8 2 3
54. J Gamrekelashvili C Kruger R von Wasielewski M Hoffmann KM Huster DH Busch MP Manns F Korangy TF Greten 2007 Necrotic tumor cell death in vivo impairs tumor-specific immune responses J Immunol 178 1573 1580
55. F Ghiringhelli L Apetoh F Housseau G Kroemer L Zitvogel 2007 Links between innate and cognate tumor immunity Curr Opin Immunol 19 224 231
56. A Giampietri MC Fioretti A Goldin E Bonmassar 1980 Drug-mediated antigenic changes in murine leukemia cells: antagonistic effects of quinacrine, an antimutagenic compound J Natl Cancer Inst 64 297 301
57. DV Gold K Schutsky D Modrak TM Cardillo 2003 Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer Clin Cancer Res 9 3929S 3937S
58. GG Gomez RB Hutchison CA Kruse 2001 Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer Cancer Treat Rev 27 375 402
59. AK Gopal JG Rajendran SH Petersdorf DG Maloney JF Eary BL Wood TA Gooley SA Bush LD Durack PJ Martin DC Matthews FR Appelbaum ID Bernstein OW Press 2002 High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma Blood 99 3158 3162
60. U Graeven B Kremer T Sudhoff B Killing F Rojo D Weber J Tillner C Unal W Schmiegel 2006 Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer Br J Cancer 94 1293 1299
61. HD Han CK Song YS Park KH Noh JH Kim T Hwang TW Kim BC Shin 2008 A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine Int J Pharm 350 27 34
62. MC Hancock BC Langton T Chan P Toy JJ Monahan RP Mischak LK Shawver 1991 A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines Cancer Res 51 4575 4580
63. R Harrop N Drury W Shingler P Chikoti I Redchenko MW Carroll SM Kingsman S Naylor R Griffiths N Steven RE Hawkins 2008 Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-Xuorouracil, leukovorin and irinotecan) is safe and induces potent immune responses Cancer Immunol Immunother 57 977 986
64. R Harrop N Drury W Shingler P Chikoti I Redchenko MW Carroll SM Kingsman S Naylor A Melcher J Nicholls H Wassan N Habib A Anthoney 2007 Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses Clin Cancer Res 13 4487 4494
65. M Hayakawa S Kawaguchi S Ishii M Murakami T Uede 1997 B7-1-transfected tumor vaccine counteracts chemotherapy-induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells Int J Cancer 71 1091 1102
66. JF Head RL Elliott JL McCoy 1993 Evaluation of lymphocyte immunity in breast cancer patients Breast Cancer Res Treat 26 77 88
67. JM Hou JY Liu L Yang X Zhao L Tian ZY Ding YJ Wen T Niu F Xiao YY Lou GH Tan HX Deng J Li JL Yang YQ Mao B Kan Y Wu Q Li YQ Wei 2005 Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities Oncology 69 81 87
68. DP Houchens E Bonmassar MR Gaston M Kende A Goldin 1976 Drug-mediated immunogenic changes of virus-induced leukemia in vivo Cancer Res 36 1347 1352
69. KA Jeglum KM Young K Barnsley A Whereat 1988 Chemotherapy versus chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma Cancer 61 2042 2050
70. TH Kang JH Lee CK Song HD Han BC Shin SI Pai CF Hung C Trimble JS Lim TW Kim TC Wu 2007 Epigallocatechin-3-gallate enhances CD8 + T cell-mediated antitumor immunity induced by DNA vaccination Cancer Res 67 802 811
71. E Kievit HM Pinedo HM Schluper E Boven 1997 Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer Int J Radiat Oncol Biol Phys 38 419 428
72. CH Kim SJ Woo JS Park HS Kim MY Park SD Park YK Hong TG Kim 2007 Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma Immunology 122 615 622
73. RT Kipp DG McNeel 2007 Immunotherapy for prostate cancer-recent progress in clinical trials Clin Adv Hematol Oncol 5 465-74 77 79
74. AH Ko 2007 Future strategies for targeted therapies and tailored patient management in pancreatic cancer Semin Oncol 34 354 364
75. EC Ko X Wang S Ferrone 2003 Immunotherapy of malignant diseases. Challenges and strategies Int Arch Allergy Immunol 132 294 309
76. HJ Ko YJ Kim YS Kim WS Chang SY Ko SY Chang S Sakaguchi CY Kang 2007 A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model Cancer Res 67 7477 7486
77. DM Kofler C Mayr CM Wendtner 2006 Current status of immunotherapy in B cell malignancies Curr Drug Targets 7 1371 1374
78. Y Kotera K Shimizu JJ Mule 2001 Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization Cancer Res 61 8105 8109
79. DV Krysko K D'Herde P Vandenabeele 2006 Clearance of apoptotic and necrotic cells and its immunological consequences Apoptosis 11 1709 1726
80. RA Lake BW Robinson 2005 Immunotherapy and chemotherapy-a practical partnership Nat Rev Cancer 5 397 405
81. RA Larson M Boogaerts E Estey C Karanes EA Stadtmauer EL Sievers P Mineur JM Bennett MS Berger CB Eten M Munteanu MR Loken JJ Van Dongen ID Bernstein FR Appelbaum 2002 Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) Leukemia 16 1627 1636
82. JY Liu Y Wu XS Zhang JL Yang HL Li YQ Mao Y Wang X Cheng YQ Li JC Xia M Masucci YX Zeng 2007 Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine Cancer Immunol Immunother 56 1597 1604
83. D Luftner D Pollmann S Schildhauer J Sehouli K Possinger 2005 Perspectives of immunotherapy in metastatic breast cancer Anticancer Res 25 4599 4604
84. ME Lutsiak RT Semnani R De Pascalis SV Kashmiri J Schlom H Sabzevari 2005 Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 105 2862 2868
85. JP Machiels RT Reilly LA Emens AM Ercolini RY Lei D Weintraub FI Okoye EM Jaffee 2001 Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Res 61 3689 3697
86. L Markasz H Skribek M Uhlin R Otvos E Flaberg S Eksborg E Olah G Stuber L Szekely 2008 Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes J Immunother 31 283 293
87. M Marty F Cognetti D Maraninchi R Snyder L Mauriac M Tubiana-Hulin S Chan D Grimes A Anton A Lluch J Kennedy K O'Byrne P Conte M Green C Ward K Mayne JM Extra 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265 4274
88. GR Masters MA Berger EF Albone 2006 Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts Gynecol Oncol 102 462 467
89. DW McMillin B Hewes B Gangadharan DR Archer RS Mittler HT Spencer 2006 Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy Hum Gene Ther 17 798 806
90. C Menard F Martin L Apetoh F Bouyer F Ghiringhelli 2008 Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity Cancer Immunol Immunother 57 1579 1587
91. E Mihich 1969 Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice Cancer Res 29 848 854
92. E Mihich 1969 Modification of tumor regression by immunologic means Cancer Res 29 2345 2350
93. E Mihich 1971 Preclinical evaluation of the interrelationships between cancer chemotherapy and immunity Natl Cancer Inst Monogr 34 90 102
94. E Mihich 2007 Anticancer drug-induced immunomodulation and cancer therapeutics Curr Cancer Ther Rev 3 174 193
95. MS Mitchell 2003 Combinations of anticancer drugs and immunotherapy Cancer Immunol Immunother 52 686 692
96. MS Mitchell 2003 Immunotherapy as part of combinations for the treatment of cancer Int Immunopharmacol 3 1051 1059
97. MB Mokyr S Dray 1983 Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide Cancer Res 43 3112 3119
98. MB Mokyr JC Hengst S Dray 1982 Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors Cancer Res 42 974 979
99. Y Motoyoshi K Kaminoda O Saitoh K Hamasaki K Nakao N Ishii Y Nagayama K Eguchi 2006 Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide Oncol Rep 16 141 146
100. P Muranski A Boni C Wrzesinski DE Citrin SA Rosenberg R Childs NP Restifo 2006 Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat Clin Pract Oncol 3 668 681
101. SS Neelapu ST Lee H Qin SC Cha AF Woo LW Kwak 2006 Therapeutic lymphoma vaccines: importance of T-cell immunity Expert Rev Vaccines 5 381 394
102. A Nicolin F Spreafico E Bonmassar A Goldin 1976 Antigenic changes of L5178Y lymphoma after treatment with 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide in vivo J Natl Cancer Inst 56 89 93
103. M Noguchi K Itoh A Yao T Mine A Yamada Y Obata M Furuta M Harada S Suekane K Matsuoka 2005 Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24 + HRPC patients Prostate 63 1 12
104. AK Nowak RA Lake AL Marzo B Scott WR Heath EJ Collins JA Frelinger BW Robinson 2003 Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells J Immunol 170 4905 4913
105. AK Nowak BW Robinson RA Lake 2003 Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors Cancer Res 63 4490 4496
106. M Obeid A Tesniere F Ghiringhelli GM Fimia L Apetoh JL Perfettini M Castedo G Mignot T Panaretakis N Casares D Metivier N Larochette P van Endert F Ciccosanti M Piacentini L Zitvogel G Kroemer 2007 Calreticulin exposure dictates the immunogenicity of cancer cell death Nat Med 13 54 61
107. M Obeid A Tesniere T Panaretakis R Tufi N Joza P van Endert F Ghiringhelli L Apetoh N Chaput C Flament E Ullrich S de Botton L Zitvogel G Kroemer 2007 Ecto-calreticulin in immunogenic chemotherapy Immunol Rev 220 22 34
108. L Orlando A Cardillo R Ghisini A Rocca A Balduzzi R Torrisi G Peruzzotti A Goldhirsch E Pietri M Colleoni 2006 Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer BMC Cancer 6 225
109. SD Park CH Kim CK Kim JA Park HJ Sohn YK Hong TG Kim 2007 Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model Vaccine 25 3485 3491
110. AR Paul PF Engstrom LM Weiner Z Steplewski H Koprowski 1986 Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM) Hybridoma 5 Suppl 1 S171 S174
111. M Pegram S Hsu G Lewis R Pietras M Beryt M Sliwkowski D Coombs D Baly F Kabbinavar D Slamon 1999 Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 2241 2251
112. MD Pegram A Lipton DF Hayes BL Weber JM Baselga D Tripathy D Baly SA Baughman T Twaddell JA Glaspy DJ Slamon 1998 Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J Clin Oncol 16 2659 2671
113. MD Pegram DJ Slamon 1999 Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity Semin Oncol 26 89 95
114. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith L Gianni J Baselga R Bell C Jackisch D Cameron M Dowsett CH Barrios G Steger CS Huang M Andersson M Inbar M Lichinitser I Lang U Nitz H Iwata C Thomssen C Lohrisch TM Suter J Ruschoff T Suto V Greatorex C Ward C Straehle E McFadden MS Dolci RD Gelber 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672
115. RJ Pietras BM Fendly VR Chazin MD Pegram SB Howell DJ Slamon 1994 Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells Oncogene 9 1829 1838
116. RJ Pietras MD Pegram RS Finn DA Maneval DJ Slamon 1998 Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs Oncogene 17 2235 2249
117. R Pinkerton 2005 Continuing challenges in childhood non-Hodgkin's lymphoma Br J Haematol 130 480 488
118. OW Press JF Eary T Gooley AK Gopal S Liu JG Rajendran DG Maloney S Petersdorf SA Bush LD Durack PJ Martin DR Fisher B Wood JW Borrow B Porter JP Smith DC Matthews FR Appelbaum ID Bernstein 2000 A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Blood 96 2934 2942
119. OW Press JM Unger RM Braziel DG Maloney TP Miller M Leblanc RI Fisher 2006 Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911 J Clin Oncol 24 4143 4149
120. OW Press JM Unger RM Braziel DG Maloney TP Miller M LeBlanc ER Gaynor SE Rivkin RI Fisher 2003 A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911 Blood 102 1606 1612
121. MC Prewett AT Hooper R Bassi LM Ellis HW Waksal DJ Hicklin 2002 Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts Clin Cancer Res 8 994 1003
122. P Rajvanshi HM Shulman EL Sievers GB McDonald 2002 Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy Blood 99 2310 2314
123. MH Ravindranath S Muthugounder N Presser S Viswanathan 2004 Anticancer therapeutic potential of soy isoflavone, genistein Adv Exp Med Biol 546 121 165
124. I Reiter B Krammer G Schwamberger 1999 Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities J Immunol 163 1730 1732
125. L Romani MC Fioretti E Bonmassar 1979 In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3, 3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo Transplantation 28 218 222
126. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684
127. SA Rosenberg ME Dudley 2004 Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes Proc Natl Acad Sci USA 101 Suppl 2 14639 14645
128. SA Rosenberg MT Lotze JC Yang PM Aebersold WM Linehan CA Seipp DE White 1989 Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients Ann Surg 210 474 484 discussion 84-5
129. SA Rosenberg JR Yannelli JC Yang SL Topalian DJ Schwartzentruber JS Weber DR Parkinson CA Seipp JH Einhorn DE White 1994 Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 J Natl Cancer Inst 86 1159 1166
130. S Samanta SM Alam S Basu T Maji DK Roy T Jha 2007 Chemoimmunotherapeutic approach to prolonged survival time in combination with immunization and glutamic Acid derivatives with antitumor activity in tumor-bearing mice Biol Pharm Bull 30 2334 2339
131. Y Sato T Fujiwara T Mine H Shomura S Homma Y Maeda N Tokunaga Y Ikeda Y Ishihara A Yamada N Tanaka K Itoh M Harada S Todo 2007 Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients Cancer Sci 98 1113 1119
132. M Schuster A Nechansky R Kircheis 2006 Cancer immunotherapy Biotechnol J 1 138 147
133. A Serrano S Tanzarella I Lionello R Mendez C Traversari F Ruiz-Cabello F Garrido 2001 Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment Int J Cancer 94 243 251
134. DM Shin NJ Donato R Perez-Soler HJ Shin JY Wu P Zhang K Lawhorn FR Khuri BS Glisson J Myers G Clayman D Pfister J Falcey H Waksal J Mendelsohn WK Hong 2001 Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer Clin Cancer Res 7 1204 1213
135. EL Sievers FR Appelbaum RT Spielberger SJ Forman D Flowers FO Smith K Shannon-Dorcy MS Berger ID Bernstein 1999 Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 93 3678 3684
136. EL Sievers RA Larson EA Stadtmauer E Estey B Lowenberg H Dombret C Karanes M Theobald JM Bennett ML Sherman MS Berger CB Eten MR Loken JJ van Dongen ID Bernstein FR Appelbaum 2001 Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 19 3244 3254
137. JG Sinkovics JC Horvath 2006 Evidence accumulating in support of cancer
138. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
139. I Smith M Procter RD Gelber S Guillaume A Feyereislova M Dowsett A Goldhirsch M Untch G Mariani J Baselga M Kaufmann D Cameron R Bell J Bergh R Coleman A Wardley N Harbeck RI Lopez P Mallmann K Gelmon N Wilcken E Wist P Sanchez Rovira MJ Piccart-Gebhart 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29 36
140. CK Song HD Han KH Noh TH Kang YS Park JH Kim ES Park BC Shin TW Kim 2007 Chemotherapy enhances CD8(+) T cell-mediated antitumor immunity induced by vaccination with vaccinia virus Mol Ther 15 1558 1563
141. GH Tan L Tian YQ Wei X Zhao J Li Y Wu YJ Wen T Yi ZY Ding B Kan YQ Mao HX Deng HL Li CH Zou CH Fu 2004 Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities Int J Cancer 112 701 706
142. J Tschmelitsch E Barendswaard C Williams Jr TJ Yao AM Cohen LJ Old S Welt 1997 Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil) Cancer Res 57 2181 2186
143. M Untch N Ditsch K Hermelink 2003 Immunotherapy: new options in breast cancer treatment Expert Rev Anticancer Ther 3 403 408
144. AJ van den Eertwegh 2005 Active specific immunotherapy in colon cancer Recent Results Cancer Res 165 260 267
145. RG van der Most A Currie BW Robinson RA Lake 2006 Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity Cancer Res 66 601 604
146. JM Vose BK Link ML Grossbard M Czuczman A Grillo-Lopez P Gilman A Lowe LA Kunkel RI Fisher 2001 Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol 19 389 397
147. MT Voso G Pantel M Weis P Schmidt S Martin M Moos AD Ho R Haas S Hohaus 2000 In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma Br J Haematol 109 729 735
148. CJ Wheeler A Das G Liu JS Yu KL Black 2004 Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination Clin Cancer Res 10 5316 5326
149. HQ Xiong A Rosenberg A LoBuglio W Schmidt RA Wolff J Deutsch M Needle JL Abbruzzese 2004 Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial J Clin Oncol 22 2610 2616
150. H Yanagimoto T Mine K Yamamoto S Satoi N Terakawa K Takahashi K Nakahara S Honma M Tanaka J Mizoguchi A Yamada M Oka Y Kamiyama K Itoh S Takai 2007 Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer Cancer Sci 98 605 611
151. S Yang FG Haluska 2004 Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways J Immunol 172 4599 4608
152. B Zhang NA Bowerman JK Salama H Schmidt MT Spiotto A Schietinger P Yu YX Fu RR Weichselbaum DA Rowley DM Kranz H Schreiber 2007 Induced sensitization of tumor stroma leads to eradication of established cancer by T cells J Exp Med 204 49 55
153. SJ Zheng SP Zheng FY Huang CL Jiao RL Wu 2007 Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model World J Gastroenterol 13 2484 2489
154. SP Zheng SJ Zheng RL Wu FY Huang LM Cao CL Jiao 2007 Enhanced efficacy in anti-tumour activity by combined therapy of recombinant FGFR-1 related angiogenesis and low-dose cytotoxic agent Eur J Cancer 43 2134 2139
155. L Zitvogel L Apetoh F Ghiringhelli G Kroemer 2008 Immunological aspects of cancer chemotherapy Nat Rev Immunol 8 59 73